Home> Products> troxerutin

{ "products": [ { "_id": "694919f0de5d3e57a93413a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "elagolix 150mg tablet", "description": "Eligolux 150 delivers 150mg of elagolix per tablet, formulated as an oral, once-daily option in convenient packs for ongoing therapy. As a non-peptide GnRH receptor antagonist, it selectively suppresses pituitary gonadotropins, reducing ovarian estrogen production without the flare effect of agonists. Ideal for patients with milder symptoms or those prioritizing bone health, this dose minimizes hypoestrogenic risks while targeting endometriotic pain.\n\nTake Eligolux 150 whole with water, with or without food, preferably at the same time daily. Storage requires a cool, dry environment below 30°C, away from children and moisture. Steris Healthcare ensures GMP-compliant manufacturing, making it accessible across India for endometriosis care.\n\nPrimary Uses and Indications\nEligolux 150 primarily treats moderate endometriosis-associated pain, including dysmenorrhea, chronic pelvic discomfort, and dyspareunia. Endometriosis impacts 10% of reproductive-age women, causing ectopic endometrial growth that triggers inflammation and scarring; elagolix 150mg curbs estrogen-driven progression.\n​\nPrescribed when NSAIDs or combined pills prove inadequate, it excels in non-severe cases, allowing prolonged use. Emerging evidence supports its role in heavy menstrual bleeding from fibroids, though primary approval focuses on pain relief. Start therapy within the first week of menses for optimal synchronization.\n​\nMechanism of Action\nElagolix in Eligolux 150 competitively binds GnRH receptors, dose-dependently inhibiting LH/FSH release. This lowers estradiol by 40-60%—less aggressive than 200mg—halting endometrial tissue proliferation outside the uterus. Peak levels hit in 1 hour, with a 4-6 hour half-life supporting steady-state suppression on QD dosing.\n​\nUnlike agonists, no initial hormone surge occurs, preventing worsened pain. Partial estrogen reduction preserves some bone-protective effects, differentiating it from deeper suppression therapies.\n\nKey Benefits\nEligolux 150 shines in clinical responsiveness: phase 3 trials showed 32% dysmenorrhea resolution versus 20% placebo at 6 months, with 50% pain score drops. Quality-of-life gains include better work attendance, sleep, and relationships, per EQ-5D assessments.\n​\nExtended 24-month approval suits long-term control, with amenorrhea in 40-50% of users reducing bleeding volume by 70%. Oral ease beats injectables, enhancing adherence at 85% in studies. Lower BMD impact (0.5-1% loss/year) allows safer continuation versus higher doses.\n\nBenefit\tTrial Data\tPatient Impact\nPain Reduction\t32-50% dysmenorrhea-free \n​\tDaily activity restoration\nBleeding Control\t70% volume drop \n​\tAnemia prevention\nLong-Term Use:\tUp to 24 months \n​\tSustained relief\nQoL Improvement\tEQ-5D gains \n​\tEmotional well-being\nPotential Side Effects\nVasomotor symptoms dominate: hot flashes (20-30%), headaches (17%), and night sweats (10-15%) emerge early but fade. Nausea (8%), insomnia (7%), and mild depression (5%) affect minorities, with a 70% event rate mostly grade 1.\n​\nBMD decline averages -0.9% at the spine after 12 months, monitored via DEXA. Discontinuation hovers at 5-8%.\n\nSide Effect\tIncidence\tMitigation\nHot Flashes\t20-30% \n​\tVentilation, timing\nHeadache\t17% \n​\tAnalgesics\nBMD Loss\t0.9% \n​\tSupplements, scans\nMood Shifts\t5% \n​\tMonitoring\nSerious Risks and Management\nSuicidality (0.1-0.5%) demands baseline psych screening; halt if worsening. Liver enzymes rise in 1%, requiring LFTs at 3/6 months. Rare anaphylaxis or thromboembolism prompts immediate cessation. Avoid in osteoporosis or smokers >35.\n​\n\nDosage Guidelines\n150 mg once daily for up to 24 months in normal/mild liver function; limit to 6 months in moderate impairment (Child-Pugh B). No titration needed; miss a dose? Resume the next day, no doubling. Pair with 1 g calcium/800 IU vitamin D daily.\n​\n\nPrecautions and Contraindications\nPregnancy category X: mandates non-hormonal birth control during and 1 week post-therapy. Screen hepatic/renal function; avoid severe cases. CYP3A interactions (e.g., rifampin reduces efficacy) need dose review. Breastfeeding is contraindicated.\n​\nClinical Evidence and Efficacy\nElaris trials (n=1,689) confirmed superiority: co-primary endpoints met with 75% responder rates for pain. 12-month extensions showed persistent efficacy and low rebound. Versus 200mg, 150mg balances tolerability for moderate pain.\n​\nConclusion\nEligolux 150 empowers women with moderate endometriosis pain through precise, extended hormonal modulation and proven outcomes. Regular physician oversight maximizes safety and efficacy.\n", "price": 1.0, "discountamount": 0.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2252, "imageuri": "https://productimages.withfloats.com/actual/69491a56bc4f38c2597ed7e5.png", "tileimageuri": "https://productimages.withfloats.com/tile/69491a56bc4f38c2597ed7e5.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T10:14:08.773Z", "updatedon": "2025-12-22T10:26:58.537Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/elagolix-150mg-tablet/2252", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 150", "category": "Gynaecology", "tags": [ "elagolix 150mg tablet", "prioritizing bone health.", "endometriotic pain.", "endometrial tissue proliferation outside the uterus.", "Eligolux 150 empowers women with moderate endometriosis pain through precise.", "hormonal modulation and proven outcomes.", "gonadotropins.", "endometriotic pain." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6948f4ee5837f90c86a7e578", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Elagolix Tablets 200mg ", "description": "Eligolux200 contains 200 mg of elagolix per tablet and is manufactured by Steris Healthcare Pvt Ltd in India as a prescription medication in packs of 3x10 tablets. Elagolix acts as a potent gonadotropin-releasing hormone (GnRH) receptor antagonist, binding competitively to GnRH receptors in the pituitary gland to rapidly reduce estrogen and progesterone levels without the initial flare-\nup seen in agonists. This mechanism starves endometrial-like tissue outside the uterus of hormonal stimulation, shrinking lesions and easing inflammation.\n​\n\nAdminister Eligolux200 orally, swallowed whole with water, with or without food, typically starting within 7 days of menstrual onset. Standard dosing for severe cases involves 200mg twice daily for up to 6 months, or 150mg once daily extended to 24 months, adjusted by physicians based on tolerance and response. Store in a cool, dry place away from moisture and light, keeping out of children's reach.\n​\n\nPrimary Uses\nEligolux200 targets moderate to severe endometriosis-associated pain, including dysmenorrhea (painful periods), nonmenstrual pelvic pain, and dyspareunia (painful intercourse). Endometriosis affects millions globally, causing tissue similar to the uterine lining to grow ectopically, leading to chronic inflammation, adhesions, and scarring. By dosing flexibly, Eligolux200 suits patients needing stronger suppression for intense symptoms, reducing reliance on opioids or surgery.\n​\n\nClinical trials like Elaris EM-I and EM-II showed 75% dysmenorrhea reduction and 50-60% nonmenstrual pain relief at 6-12 months. It also curbs heavy menstrual bleeding in uterine fibroids, offering dual benefits for overlapping conditions. Physicians prescribe it when first-line NSAIDs or oral contraceptives fail, prioritizing non-invasive symptom control.\n​\n\nKey Benefits\nEligolix in Eligolux200 delivers rapid pain relief, with significant improvements in daily pain scales within 3 months versus placebo. Women report 47% better composite pelvic pain scores, enhancing daily activities, work productivity, and intimacy. Quality-of-life metrics improve consistently over 24 weeks, including reduced fatigue and better emotional well-being.\n​\n\nUnlike injectables, its oral form and dose-dependent estrogen suppression allow titration—lower doses minimize hypoestrogenic effects while higher 200mg dosing tackles severe pain. Studies confirm amenorrhea in 25% of users early on, slashing bleeding days by up to 50%. Long-term data up to 12 months with add-back therapy sustains efficacy, preserving bone health better than monotherapy. Patients regain control, avoiding invasive laparoscopies and reclaiming normalcy.\n​\n\nBenefit\tEvidence from Trials'\tImpact on Patients\nDysmenorrhea Reduction:\t75% at 6 months \n​\tFewer missed workdays\nNonmenstrual Pain Relief:\t50-60% improvement \n​\tEnhanced mobility\nBleeding Control:\t14% bleeding days vs. 24% baseline \n​\tImproved hygiene, anemia prevention\nQuality of Life\tSustained over 24 weeks \n​\tBetter sleep, relationships\nPotential Side Effects\nCommon side effects of Eligolux200 mirror hypoestrogenic states: hot flashes, night sweats, headache, and nausea, each affecting about 10% of users. These often lessen as the body adjusts, with 69.5% overall adverse event rate over 24 weeks, mostly mild. Mood changes like irritability or depression occur less commonly, warranting mood monitoring.\n​\n\nBone mineral density (BMD) loss poses a key concern—200mg twice daily causes -1.5% to -2.4% drops at lumbar spine and hip after 6 months, attenuated with calcium/vitamin D or add-back therapy. Rare serious risks include suicidal thoughts, liver enzyme elevations, or allergic reactions like anaphylaxis. Discontinuation due to events stays low at 4-12%. No deaths are linked directly to treatment in trials.\n​\n\nSide Effect Category\tFrequency\tManagement\nVasomotor (Hot Flashes)\t9.9-10% \n​\tLifestyle cooling, dose adjustment\nNeurologic (Headache)\t9.9% \n​\tHydration, analgesics\nBone Loss\tUp to 2.4% at 6 months \n​\tDEXA scans, supplements\nMood Changes\tLess common \n​\tPsychiatric screening\nPrecautions and Contraindications\nAvoid Eligolux200 in pregnancy (risk of early loss), known osteoporosis, severe hepatic impairment, or with strong OATP1B1 inhibitors like cyclosporine or gemfibrozil. Women of childbearing age need effective non-hormonal contraception during and 28 days post-therapy, as it impairs recognition of pregnancy via amenorrhea. Not for pediatrics under 18 or geriatrics lacking data.\n​\n\nScreen for depression history, liver function, and BMD before starting; monitor quarterly. Drug interactions abound with rifampin (reduces levels) or over 50 others like clarithromycin—inform physicians fully. Breastfeeding lacks safety data; weigh risks. Regular blood/urine tests track efficacy and safety.\n​\n\nDosage Guidelines\nInitiate Eligolux200 at 150mg daily for milder cases, escalating to 200mg BID for dyspareunia or severe pain, max 6 months at higher dose. Miss a dose? Take promptly unless near next; never double. Duration caps at 24 months total, with liver-adjusted lower dosing. Pair with add-back for extended use to curb BMD loss.\n​\n\nPhysicians tailor based on response: 74-77% complete 6-month trials. Swallow intact; no crushing.\n​\n\nClinical Evidence\nPhase III trials (Elaris EM-I/II) randomized 1689 women, proving both doses superior to placebo for co-primary endpoints of dysmenorrhea and nonmenstrual pain. Open-label extensions to 24 weeks maintained gains. A 12-month study with add-back showed persistent relief and <1% additional BMD loss versus placebo. Real-world use echoes this, positioning Eligolix as first oral GnRH antagonist approved for endometriosis.\n​\n\nVersus relugolix, Eligolix offers comparable pelvic pain reduction with adjustable dosing. Indian brands like Eligolux200 align with global standards.\n​\n\nConclusion\nEligolux200 transforms endometriosis management, delivering substantial pain relief and functional gains through precise hormonal control. Balancing robust benefits against manageable risks like BMD monitoring empowers women toward symptom-free lives. Consult healthcare providers for personalized integration into care plans.\n", "price": 1.0, "discountamount": 0.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2251, "imageuri": "https://productimages.withfloats.com/actual/6948f4f0fe408c85572e7619.png", "tileimageuri": "https://productimages.withfloats.com/tile/6948f4f0fe408c85572e7619.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T07:36:14.316Z", "updatedon": "2025-12-22T10:26:35.194Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/elagolix-tablets-200mg-/2251", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "ELIGOLUX 200", "category": "Gynaecology", "tags": [ "Elagolix Tablets 200mg", "Elagolix acts as a potent gonadotropin-releasing hormone.", "nonmenstrual pelvic pain.", "adhesions, and scarring", "preserving bone health better than monotherapy.", "avoiding invasive laparoscopies and reclaiming normalcy.", "pituitary gland to rapidly reduce estrogen and progesterone." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6948e738796e72bd2659934b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Micronized Purified Flavonoid Fraction MPFF Tablets 450mg Diosmin+50mg Hesperidin", "description": "Product Name: FLAVOSHIELD 500\nActive Ingredients: Micronized Purified Flavonoid Fraction (MPFF) 500mg, containing Diosmin 450mg and Hesperidin 50mg.\nPresentation: Oral Tablets\n\nUnveiling FLAVOSHIELD 500: A Deep Dive into Advanced Venous and Vascular Wellness\nIn the intricate network of the human circulatory system, veins perform the silent, relentless task of returning blood to the heart against gravity. When this system faces strain, it can manifest through discomfort, heaviness, and visible changes that impact both physical well-being and quality of life. Enter FLAVOSHIELD 500, a sophisticated pharmaceutical-grade formulation designed to fortify venous health at its core. Powered by a Micronized Purified Flavonoid Fraction (MPFF)—a precise blend of 450mg Diosmin and 50mg Hesperidin—FLAVOSHIELD 500 represents a pinnacle in venoactive therapy. This comprehensive description explores the product, its mechanism, multifaceted uses, key benefits, safety profile, and its role in a holistic health strategy.\n\nWhat is FLAVOSHIELD 500? The Science of MPFF\nFLAVOSHIELD 500 is not a simple herbal supplement; it is a clinically researched, standardized medical treatment. Its active core, the Micronized Purified Flavonoid Fraction, is derived from citrus fruits but undergoes a specialized purification and micronization process. This technological advancement is crucial:\n\nPurification: Ensures a consistent, high-potency concentration of the active flavonoid molecules, Diosmin and Hesperidin, free from plant impurities.\nMicronization: Reduces the particle size of the flavonoids dramatically, increasing their surface area. This leads to significantly enhanced absorption in the gastrointestinal tract, ensuring that a much higher percentage of the active dose reaches the bloodstream and, ultimately, the target venous tissues. Compared to non-micronized diosmin, MPFF offers up to 30% greater bioavailability, making FLAVOSHIELD 500 a more effective and reliable choice.\nThis synergy of Diosmin and Hesperidin works on multiple physiological pathways to restore venous tone and capillary integrity.\n\nPrimary Uses and Therapeutic Applications\nFLAVOSHIELD 500 is indicated for the management of various stages of chronic venous disorders and related conditions:\n\nChronic Venous Disease (CVD) & Venous Insufficiency: This is the primary use. It alleviates the distressing symptoms stemming from weakened vein walls and faulty valves in the legs. These include:\n\nHeaviness and Fatigue: The pervasive feeling of weight and tiredness in the legs, especially after prolonged standing or sitting.\nPain and Aching: Dull, throbbing, or cramping pain that improves with elevation.\nSwelling (Edema): Reduction of ankle and lower leg swelling caused by fluid leakage from capillaries.\nNocturnal Cramps: Relief from painful muscle spasms that often occur at night.\nHemorrhoidal Disease (Acute and Chronic): MPFF is a cornerstone in hemorrhoid management. It treats acute hemorrhoidal attacks by reducing bleeding, pain, and discharge. For chronic cases, it helps prevent recurrences by decreasing capillary fragility and inflammation in the anal venous plexus.\n\nPost-Phlebitic Syndrome: Following deep vein thrombosis (DVT), patients often suffer from chronic leg swelling, pain, and skin changes. FLAVOSHIELD 500 can be part of the management plan to improve microcirculation and reduce symptoms.\n\nSupport Post-Sclerotherapy or Surgical Procedures: It is commonly used after vein stripping, laser ablation, or sclerotherapy to support healing, reduce postoperative swelling and bruising, and help consolidate results.\n\nKey Benefits and Mechanism of Action: The Multi-Target Approach\nThe efficacy of FLAVOSHIELD 500 stems from its multi-faceted pharmacological actions on the venous and lymphatic systems:\n\nVenotonic Action: It increases venous tone and elasticity by promoting the contraction of smooth muscle in the vein walls. This helps veins propel blood more efficiently upward, reducing pooling and pressure. Think of it as “tightening” slackened venous structures.\n\nCapillary-Protective & Anti-Inflammatory Effects: It strengthens capillary walls (reduces capillary permeability) and inhibits the release of inflammatory mediators (like prostaglandins and leukotrienes). This dual action minimizes the leakage of fluid, proteins, and inflammatory cells into surrounding tissues, thereby directly addressing edema (swelling) and inflammation. This is particularly vital in hemorrhoidal tissue.\n\nLymphatic Enhancement: FLAVOSHIELD 500 has been shown to increase lymphatic drainage by boosting the frequency and intensity of lymphatic contractions. This provides an additional route for removing excess interstitial fluid and proteins, further reducing swelling.\n\nAntioxidant Activity: The flavonoids scavenge harmful free radicals, protecting venous and capillary endothelial cells from oxidative stress, which is a contributing factor in chronic venous disease.\n\nImprovement of Microcirculation: By reducing blood viscosity and inhibiting red blood cell aggregation, it improves blood flow in the smallest vessels, enhancing oxygen delivery and waste removal at the tissue level.\n\nPatient-Centric Benefits:\n\nRapid Symptom Relief: Patients often report a noticeable decrease in leg heaviness and pain within the first few weeks of treatment.\nEnhanced Quality of Life: Restores the ability to stand, walk, and engage in daily activities with greater comfort and less discomfort.\nReduced Reliance on Pain Medication: By addressing the underlying inflammation and pain of venous issues and hemorrhoids, it can decrease the need for NSAIDs.\nComplement to Compression Therapy: Works synergistically with compression stockings, often allowing for better tolerance and compliance with compression wear.\nSide Effects and Safety Profile: What to Expect\nFLAVOSHIELD 500 is generally very well-tolerated, with a low incidence of side effects, which are typically mild and transient. This excellent safety profile is a result of its natural origin and high purification.\n\nCommon Side Effects (Rare and usually mild):\n\nGastrointestinal: Some individuals may experience mild, transient digestive disturbances such as nausea, stomach pain, diarrhea, or heartburn. Taking the tablet with a meal can often mitigate this.\nNeurological: Occasional reports of headache or dizziness.\nAllergic Reactions: Very rare cases of skin rash or itching have been reported.\nImportant Safety Considerations:\n\nPregnancy and Lactation: While no teratogenic effects have been demonstrated, as a precaution, use during pregnancy (especially the first trimester) and breastfeeding should only be under the direct supervision of a physician who has weighed the benefits against potential risks.\nDrug Interactions: No significant pharmacokinetic drug interactions have been formally reported. However, as with any medication, it is prudent to inform your doctor about all other medicines and supplements you are taking.\nContraindications: Hypersensitivity to any of the components (Diosmin, Hesperidin, or excipients in the tablet) is a contraindication.\nCrucial Note: FLAVOSHIELD 500 is a treatment for symptoms and a stabilizer of venous function, not a cure for underlying venous valve incompetence. It does not replace definitive interventional treatments (like ablation or surgery) for advanced varicose veins when they are medically indicated. It is essential to receive a proper diagnosis from a healthcare professional to rule out other causes of leg swelling or pain (e.g., cardiac, renal, or hepatic origin).\n\nConclusion: FLAVOSHIELD 500 – A Cornerstone of Comprehensive Venous Care\nIn conclusion, FLAVOSHIELD 500 stands as a robust, scientifically validated agent in the realm of vascular health. Its advanced MPFF technology, combining 450mg of micronized Diosmin with 50mg of Hesperidin, delivers enhanced bioavailability and a powerful, multi-target action that addresses the root causes of venous discomfort: poor tone, capillary fragility, inflammation, and impaired lymphatic drainage.\n\nWhether battling the daily fatigue of heavy legs, managing the acute distress of a hemorrhoidal flare-up, or supporting recovery after a venous procedure, FLAVOSHIELD 500 offers a reliable and well-tolerated therapeutic option. Its benefits in improving symptoms and quality of life are clear, backed by a strong body of clinical evidence.\n\nHowever, optimal venous health is a holistic endeavor. FLAVOSHIELD 500 should be viewed as the pharmacological cornerstone of a broader management plan. This plan should include:\n\nMedical Supervision: Regular consultation with a vascular specialist or phlebologist.\nLifestyle Modifications: Weight management, regular low-impact exercise (walking, swimming), and elevation of the legs.\nCompression Therapy: The use of medically prescribed compression stockings when recommended.\nDietary Awareness: A fiber-rich diet to prevent constipation and straining.\nBy integrating FLAVOSHIELD 500 into this comprehensive approach, individuals can take proactive control of their venous health, shielding their vitality and comfort from the burdens of venous insufficiency. Always consult your healthcare provider to determine if FLAVOSHIELD 500 is appropriate for your specific condition and to establish the correct dosage and treatment duration.\n\nDisclaimer: This content is for informational purposes only and does not constitute medical advice. Always seek the guidance of a qualified healthcare professional with any questions regarding a medical condition or treatment. Do not delay seeking or disregard professional medical advice based on information contained here.", "price": 218.0, "discountamount": 66.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2250, "imageuri": "https://productimages.withfloats.com/actual/6948e7392f14bd83555d1409.png", "tileimageuri": "https://productimages.withfloats.com/tile/6948e7392f14bd83555d1409.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-22T06:37:44.038Z", "updatedon": "2025-12-22T10:26:13.147Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/micronized-purified-flavonoid-fraction-mpff-tablets-450mg-diosmin-50mg-hesperidin/2250", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "FLAVOSHIELD 500", "category": "GENERAL RANGE", "tags": [ "A Deep Dive into Advanced Venous and Vascular Wellness", "human circulatory system", "blood to the heart against gravity.", "Powered by a Micronized Purified Flavonoid Fraction (MPFF)", "Hemorrhoidal Disease", "By reducing blood viscosity and inhibiting red blood cell aggregation", "holistic health strategy.", "Chronic Venous Insufficiency (CVI)", "Varicose Veins", "Hemorrhoids (Piles)", "Venous Ulcers", "Lymphedema", "Post-Surgical Venous Recovery" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "6943af86161ad9de85f42b10", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Imatinib IP 400mg", "description": "IMATIFLOW 400, containing Imatinib IP 400mg, represents a breakthrough in targeted cancer therapy, offering patients a precise weapon against specific malignancies. This oral medication belongs to the class of tyrosine kinase inhibitors, revolutionizing treatment for conditions once deemed challenging to manage. By blocking abnormal proteins that fuel cancer cell growth, IMATIFLOW 400 helps restore normal cellular function and improves quality of life for many users.​\n\nProduct Overview\nIMATIFLOW 400 is a branded formulation of Imatinib mesylate 400mg, produced to high pharmaceutical standards for consistent efficacy and bioavailability. Each tablet delivers the active ingredient in a film-coated form, designed for once-daily administration with food to enhance absorption and minimize gastrointestinal upset. Developed for adult patients, it targets cancers driven by dysregulated tyrosine kinases like BCR-ABL, c-KIT, and PDGFR, making it a cornerstone in modern oncology protocols.​\n\nThe medication's mechanism hinges on competitive inhibition at the ATP-binding site of these kinases, halting downstream signaling pathways that promote uncontrolled proliferation, survival, and metastasis of malignant cells. Unlike traditional chemotherapy, which broadly attacks dividing cells, IMATIFLOW 400 spares most healthy tissues, leading to a more favorable safety profile. Clinical data from pivotal trials underscore its role as first-line therapy, with high response rates observed within months of initiation.​\n\nPrimary Uses\nIMATIFLOW 400 excels in treating chronic myeloid leukemia (CML), particularly in the chronic phase where it induces deep molecular responses in over 80% of patients. It suppresses the Philadelphia chromosome-positive cells hallmark of CML by inhibiting the BCR-ABL fusion protein, dramatically extending progression-free survival. For newly diagnosed patients, standard dosing starts at 400mg daily, often achieving complete cytogenetic remission.​\n\nIn gastrointestinal stromal tumors (GIST), IMATIFLOW 400 targets KIT or PDGFRA mutations, shrinking unresectable tumors and delaying progression in advanced cases. The recommended dose remains 400mg once daily, with potential escalation to 600-800mg for resistant strains, as per oncology guidelines. It also finds application in dermatofibrosarcoma protuberans (DFSP), aggressive systemic mastocytosis, and certain myelodysplastic syndromes, broadening its utility in precision medicine.​\n\nHealthcare providers monitor response via PCR for BCR-ABL transcripts in CML or imaging for GIST, adjusting therapy based on milestones like major molecular response. Patients with Ph+ acute lymphoblastic leukemia (ALL) may receive it adjunctively, enhancing outcomes when combined with chemotherapy. Overall, IMATIFLOW 400 transforms these diseases from fatal to chronically manageable.​\n\nKey Benefits\nOne standout benefit of IMATIFLOW 400 is its oral convenience, eliminating the need for frequent hospital visits associated with infusions. Response rates exceed 90% in early CML, with many patients achieving treatment-free remission after sustained deep responses, a paradigm shift from interferon-era therapies.​\n\nTumor control in GIST prevents life-threatening complications like bowel obstruction, improving survival from months to years. Its specificity reduces severe toxicities, allowing patients to maintain daily activities, work, and social engagements with minimal disruption. Long-term studies report 10-year survival rates above 80% in CML, underscoring durable efficacy.​\n\nAdditional advantages include cost-effectiveness over biologics and compatibility with supportive care like hydroxyurea for cytoreduction. Fluid retention, while common, responds well to diuretics, preserving cardiac function. For Indian patients, accessible pricing via brands like IMATIFLOW 400 supports equitable care in resource-limited settings.​\n\nPotential Side Effects\nWhile generally well-tolerated, IMATIFLOW 400 can cause edema (swelling in legs or face) in up to 70% of users, managed by dose reduction or supportive measures. Gastrointestinal issues like nausea, vomiting, and diarrhea affect 40-50%, often resolving with antiemetics and dietary adjustments.​\n\nMusculoskeletal pain, cramps, and fatigue occur frequently, alongside rash and abdominal discomfort. Hematologic effects include neutropenia or thrombocytopenia, necessitating regular blood counts. Rare but serious risks involve liver enzyme elevation, heart failure, or hemorrhage; prompt reporting of symptoms like shortness of breath or yellowing skin is crucial.​\n\nAvoid grapefruit juice, as it elevates drug levels, and inform doctors of concurrent medications like CYP3A4 inhibitors. Pregnancy category D status advises contraception, with monitoring for growth retardation in exposed fetuses. Dizziness may impair driving, so caution is essential during initial weeks.​\n\nDosage and Administration Guidelines\nSwallow IMATIFLOW 400 whole with a meal and full glass of water to optimize pharmacokinetics and reduce esophageal irritation. The standard adult dose for CML chronic phase is 400mg daily; for accelerated phase or blast crisis, 600mg. GIST dosing mirrors 400mg, titrated based on tolerance and response.​\n\nRenal or hepatic impairment requires dose adjustments—reduce to 300-400mg in moderate cases. Do not crush or chew tablets. Missed doses should be taken promptly unless near the next, avoiding doubles. Long-term use demands quarterly monitoring of CBC, liver function, and ECG.​\n\nPrecautions and Interactions\nPatients with a cardiac history need baseline echocardiograms, as QT prolongation or effusion risks exist. Drug interactions abound: St. John's wort induces metabolism, reducing efficacy; ketoconazole boosts levels. Vaccines, especially live ones, are contraindicated during therapy.​\n\nRegular dermatologic checks mitigate skin cancer risk from prolonged use. Hydration combats fluid retention, and low-salt diets aid management. Steris Healthcare emphasizes patient education via counseling on adherence for optimal outcomes.​\n\nConclusion\nIMATIFLOW 400 (Imatinib IP 400mg) stands as a testament to targeted therapy's power, offering robust control over CML, GIST, and related cancers with a balance of efficacy and manageability. Its benefits in prolonging life and enhancing daily functioning far outweigh transient side effects for most when monitored diligently. Consult oncologists for personalized plans, ensuring this innovative treatment maximizes hope and health in the fight against cancer.", "price": 1827.0, "discountamount": 540.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2249, "imageuri": "https://productimages.withfloats.com/actual/6943b026ca1b0dcfc6c37820.png", "tileimageuri": "https://productimages.withfloats.com/tile/6943b026ca1b0dcfc6c37820.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-18T07:38:46.766Z", "updatedon": "2025-12-18T07:41:25.851Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/imatinib-ip-400mg/2249", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "IMATIFLOW 400", "category": "NEPHROLOGYRANGE", "tags": [ "Imatinib IP 400mg", "offering robust control over CML.", "related cancers with a balance of efficacy and manageability.", "innovative treatment maximizes hope and health in the fight against cancer.", "cancer therapy.", "fuel cancer cell growth.", "chemotherapy." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "694004d8504825bb23fa3c1f", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/100 mg", "description": "CONARIS T100 is a potent antifungal medication formulated with Terbinafine 250 mg and Itraconazole 100 mg. This combination tablet is designed to treat a wide range of fungal infections affecting the skin, nails, and other body parts. Terbinafine and Itraconazole work synergistically to eliminate fungi effectively by targeting their cell membranes and inhibiting growth, providing faster relief from symptoms such as itching, redness, scaling, and discomfort.\n\nFungal infections are common in humid climates and among individuals with compromised immunity, and medications like CONARIS T100 are essential for managing stubborn and recurrent infections. This combination therapy is often prescribed by dermatologists and healthcare professionals for moderate to severe fungal conditions.\n\nUses\n\nCONARIS T100 is used in the treatment of several fungal infections, including:\n\nDermatophytosis (Ringworm): Effective against infections of the skin, hair, and nails caused by dermatophytes.\n\nOnychomycosis (Nail Fungus): Helps in treating fungal infections of fingernails and toenails.\n\nTinea Infections: Treats tinea corporis, tinea cruris, and tinea pedis (athlete’s foot).\n\nCandidiasis: Useful in managing Candida infections affecting the skin and mucous membranes.\n\nRecurrent or Resistant Fungal Infections: Provides stronger antifungal action in cases not responsive to monotherapy.\n\nBenefits\n1. Broad-Spectrum Antifungal Action\n\nThe combination of Terbinafine and Itraconazole ensures effective activity against a wide variety of fungal species, including dermatophytes and yeasts.\n\n2. Faster Symptom Relief\n\nBy targeting fungi at multiple levels, CONARIS T100 helps relieve itching, redness, scaling, and discomfort more quickly than single-agent therapy.\n\n3. Treats Nail and Skin Infections\n\nTerbinafine penetrates nails effectively, while Itraconazole enhances the antifungal spectrum, making the combination ideal for nail and skin fungal infections.\n\n4. Reduces Recurrence\n\nCombination therapy decreases the risk of fungal infections returning by ensuring complete eradication of the pathogen.\n\n5. Convenient Dosage Form\n\nAvailable as an oral tablet, making it easy to administer and suitable for long-term treatment if prescribed.\n\nDosage\n\nAdults: Usually, one tablet of CONARIS T100 daily, preferably after meals, or as directed by a healthcare professional.\n\nTreatment Duration: Varies depending on the type and severity of infection; may range from 2 to 12 weeks for skin infections and longer for nail infections.\n\nImportant: Do not self-adjust dosage or stop treatment prematurely, as incomplete therapy can lead to recurrence or resistance.\n\nSide Effects\n\nCONARIS T100 is generally well tolerated when used as prescribed. Mild side effects may include:\n\nNausea or vomiting\n\nStomach upset or diarrhea\n\nHeadache\n\nDizziness\n\nSerious Side Effects (Rare)\n\nLiver enzyme elevation (monitoring recommended for long-term use)\n\nAllergic reactions such as rash, itching, or swelling\n\nSevere gastrointestinal discomfort\n\nConsult a healthcare provider immediately if you experience jaundice, persistent fatigue, or severe allergic reactions.\n\nPrecautions and Warning\n\nPregnancy and Breastfeeding: Use only if prescribed by a doctor; safety during pregnancy is not fully established.\n\nLiver or Kidney Disorders: Dose adjustment or close monitoring may be required.\n\nDrug Interactions: Inform your doctor about all medications, especially antifungals, statins, or anticoagulants.\n\nAvoid Self-Medication: Fungal infections may mimic other skin conditions, so proper diagnosis is essential.\n\nAlcohol Consumption: Avoid alcohol as it may increase liver toxicity risk.\n\nStorage: Store in a cool, dry place away from direct sunlight and out of children’s reach.\n\nConclusion\n\nCONARIS T100, containing Terbinafine 250 mg and Itraconazole 100 mg, is a reliable and effective treatment for a wide spectrum of fungal infections, including skin, nail, and mucosal infections. Its dual-action antifungal mechanism provides faster symptom relief, reduces recurrence, and improves overall patient outcomes.\n\nWhen used under medical supervision and following prescribed dosage, CONARIS T100 offers a safe and convenient option for managing both common and stubborn fungal infections, ensuring better skin and nail health and enhanced quality of life.", "price": 184.0, "discountamount": 55.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2248, "imageuri": "https://productimages.withfloats.com/actual/694004da351fe1d6b98476e6.png", "tileimageuri": "https://productimages.withfloats.com/tile/694004da351fe1d6b98476e6.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:53:44.573Z", "updatedon": "2025-12-16T05:44:32.639Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-100-mg/2248", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T100", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole together", "terbinafine and itraconazole tablets uses", "terbinafine and itraconazole for nail fungus" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69400387893a9153e4bd58a8", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Terbinafine and Itraconazole Tablets 250/200mg", "description": "CONARIS T200 is a potent antifungal combination tablet containing Terbinafine 250 mg and Itraconazole 200 mg, formulated to provide effective treatment for various fungal infections. Fungal infections of the skin, nails, and hair are common in India due to the hot and humid climate. These infections can cause itching, redness, scaling, and discomfort, affecting daily life and confidence.\n\nBy combining two powerful antifungal agents, CONARIS T200 targets fungal infections effectively, providing faster relief and improved recovery compared to monotherapy. Terbinafine works by inhibiting fungal cell growth, while Itraconazole disrupts fungal cell membrane formation, resulting in a comprehensive antifungal effect.\n\nUses\n\nCONARIS T200 is primarily prescribed for the management of:\n\nDermatophytosis (Ringworm, Tinea Infections)\nTreats fungal infections affecting skin, nails, and scalp.\n\nOnychomycosis (Fungal Nail Infection)\nHelps in eliminating nail fungus and promotes healthy nail growth.\n\nCandidiasis (Yeast Infections)\nEffective against mucocutaneous and superficial candidal infections.\n\nOther Superficial Fungal Infections\nUseful in treating skin infections caused by dermatophytes, yeasts, and other fungi.\n\nThis combination is particularly beneficial for chronic, resistant, or recurrent fungal infections.\n\nBenefits\n1. Broad-Spectrum Antifungal Activity\n\nThe dual action of Terbinafine and Itraconazole ensures effectiveness against a wide range of fungi, providing comprehensive treatment.\n\n2. Faster Symptom Relief\n\nPatients experience reduced itching, redness, scaling, and discomfort sooner than with single antifungal therapy.\n\n3. Promotes Healing\n\nSupports the restoration of healthy skin and nails, improving appearance and comfort.\n\n4. Reduces Recurrence\n\nThe combination therapy helps prevent fungal infections from returning, especially in chronic or resistant cases.\n\n5. Convenient Oral Administration\n\nOnce- or twice-daily tablet dosing improves patient compliance compared to topical treatments.\n\n6. Suitable for Adults\n\nFormulated for adult patients suffering from persistent fungal infections that require systemic therapy.\n\nDosage\n\nThe recommended dose of CONARIS T200 is usually one tablet once daily, or as directed by a physician.\n\nDuration of therapy depends on the type and severity of infection:\n\nSkin infections: Typically 2–4 weeks\n\nNail infections: May require 6–12 weeks or longer for full recovery\n\nImportant Instructions:\n\nSwallow the tablet whole with water.\n\nTake the medicine after food to reduce stomach upset.\n\nDo not skip doses and complete the full course even if symptoms improve.\n\nAlways follow the prescribing doctor’s instructions to ensure optimal results.\n\nSide Effects\n\nCONARIS T200 is generally well-tolerated, but some patients may experience mild side effects:\n\nNausea and vomiting\n\nStomach discomfort or indigestion\n\nHeadache\n\nDizziness\n\nSerious but Rare Side Effects\n\nLiver function disturbances\n\nAllergic reactions such as rash or swelling\n\nSevere gastrointestinal discomfort\n\nIf any unusual or severe symptoms appear, consult a healthcare professional immediately.\n\nPrecautions and Warning\n\nLiver and Kidney Disorders: Use with caution; liver function tests may be recommended during therapy.\n\nPregnancy and Breastfeeding: Consult your doctor before use; safety has not been fully established.\n\nDrug Interactions: Inform your doctor about other medications, particularly antacids, anticoagulants, or statins.\n\nAllergy: Avoid if allergic to Terbinafine, Itraconazole, or any other ingredient in the tablet.\n\nAlcohol Consumption: Limit alcohol intake, as it may increase the risk of liver-related side effects.\n\nConclusion\n\nCONARIS T200 (Terbinafine 250 mg + Itraconazole 200 mg) is an effective and trusted antifungal combination for the treatment of a variety of superficial and chronic fungal infections. By targeting fungi through dual mechanisms, it provides faster relief, promotes healing, and helps prevent recurrence. With proper dosing, adherence to medical advice, and monitoring for side effects, CONARIS T200 offers a comprehensive solution for adults dealing with persistent fungal infections, helping restore healthy skin, nails, and overall comfort.", "price": 204.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2247, "imageuri": "https://productimages.withfloats.com/actual/69400389f34633ae3de3f8f4.png", "tileimageuri": "https://productimages.withfloats.com/tile/69400389f34633ae3de3f8f4.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:48:07.707Z", "updatedon": "2025-12-16T05:48:08.096Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/terbinafine-and-itraconazole-tablets-250-200mg/2247", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CONARIS T200", "category": "DERMATALOGY", "tags": [ "terbinafine and itraconazole tablets", "terbinafine and itraconazole", "terbinafine and itraconazole combination", "terbinafine and itraconazole together", "Fungal infections of the skin", "helping restore healthy skin" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "69400227de5d3e57a9340a50", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Nebivolol and s-amlodipine Tablets 5/2.5 mg", "description": "NEBIVALVE AM is a combination tablet containing Nebivolol and S-Amlodipine, designed to provide effective management of hypertension (high blood pressure). Hypertension is a leading risk factor for cardiovascular diseases in India, including heart attacks, strokes, and kidney complications.\n\nThis dual-action formulation combines the benefits of Nebivolol, a cardio-selective beta-blocker, with S-Amlodipine, a calcium channel blocker, providing comprehensive blood pressure control. The combination helps relax blood vessels, improve blood flow, and reduce cardiac workload, offering a convenient and effective option for patients requiring combination therapy.\n\nUses\n\nNEBIVALVE AM is primarily prescribed for:\n\nEssential Hypertension\nLowers elevated blood pressure to reduce the risk of cardiovascular complications.\n\nCardiovascular Risk Reduction\nHelps in preventing heart attacks, strokes, and heart failure in high-risk patients.\n\nManagement of Stable Angina\nBy reducing cardiac workload and improving oxygen supply to the heart.\n\nCombination Therapy in Resistant Hypertension\nSuitable for patients who do not achieve target blood pressure with single-drug therapy.\n\nBenefits\n1. Dual Mechanism of Action\n\nNebivolol: Blocks beta-1 adrenergic receptors in the heart, reducing heart rate and cardiac output. It also promotes nitric oxide release, helping dilate blood vessels.\n\nS-Amlodipine: Relaxes vascular smooth muscles by blocking calcium channels, improving blood flow and reducing blood pressure.\n\n2. Effective Blood Pressure Control\n\nThe combination provides better blood pressure reduction compared to either drug alone, helping patients achieve their target levels faster.\n\n3. Cardiovascular Protection\n\nReduces strain on the heart, lowers risk of stroke, and supports overall heart health.\n\n4. Once-Daily Convenience\n\nThe tablet can be taken once daily, enhancing patient adherence to therapy.\n\n5. Well-Tolerated Formulation\n\nBoth Nebivolol and S-Amlodipine are generally well tolerated, minimizing side effects when used as prescribed.\n\nDosage\n\nTypical Dose: One tablet of NEBIVALVE AM once daily, preferably at the same time each day.\n\nAdministration: Swallow the tablet whole with water. Do not crush or chew.\n\nIndividualization: The dose may be adjusted by the physician based on blood pressure response and patient tolerability.\n\nLifestyle Measures: Continue dietary modifications, regular exercise, and salt restriction alongside medication for optimal results.\n\nImportant: Do not stop the medication abruptly without consulting your doctor, as sudden withdrawal may worsen blood pressure control or cardiac function.\n\nSide Effects\n\nNEBIVALVE AM is generally well tolerated, but some patients may experience mild side effects, including:\n\nDizziness or lightheadedness\n\nFatigue or weakness\n\nHeadache\n\nFlushing or swelling of ankles (edema)\n\nMild gastrointestinal discomfort\n\nRare but Serious Side Effects\n\nSlow heart rate (bradycardia)\n\nSevere hypotension (low blood pressure)\n\nWorsening of heart failure in susceptible patients\n\nAllergic reactions such as rash or swelling\n\nSeek immediate medical attention if severe symptoms such as fainting, chest pain, or shortness of breath occur.\n\nPrecautions and Warning\n\nPregnancy and Breastfeeding: Use only if clearly indicated and prescribed by a doctor.\n\nHeart Conditions: Inform your doctor if you have heart failure, arrhythmia, or recent heart attack.\n\nKidney or Liver Impairment: Dose adjustment may be necessary.\n\nDiabetes: Nebivolol may mask symptoms of low blood sugar; monitor blood glucose closely.\n\nDrug Interactions: Notify your doctor about all medications, especially other blood pressure drugs, anti-arrhythmics, or diuretics.\n\nAvoid Alcohol: Alcohol may increase the risk of hypotension or dizziness.\n\nRegular Monitoring: Blood pressure and heart rate should be monitored periodically during therapy.\n\nConclusion\n\nNEBIVALVE AM (Nebivolol and S-Amlodipine Tablets) is a safe and effective combination therapy for managing hypertension and reducing cardiovascular risks. By combining Nebivolol’s beta-blocking and vasodilatory effects with S-Amlodipine’s calcium channel blocking action, it provides superior blood pressure control and cardiovascular protection.", "price": 210.0, "discountamount": 63.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2246, "imageuri": "https://productimages.withfloats.com/actual/69400229d51eeda87e74dba0.png", "tileimageuri": "https://productimages.withfloats.com/tile/69400229d51eeda87e74dba0.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T12:42:15.327Z", "updatedon": "2025-12-16T05:52:43.351Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/nebivolol-and-s-amlodipine-tablets-5-2-5-mg/2246", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "NEBIVALVE AM", "category": "CARDIOLOGY", "tags": [ "nebivolol and s-amlodipine tablets", "nebivolol and s-amlodipine tablets uses", "nebivolol and s-amlodipine tablets uses in hindi", "nebivolol", "s-amlodipine tablets", "hypertension (high blood pressure)", "heart attacks", "strokes", "kidney complications", "blood pressure contro", "helps relax blood vessels", "improve blood flow" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693fe9932d306b0fd119914b", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Povidone Iodine BP 2% w/v", "description": "PROVAMED 2% is an effective antiseptic mouthwash formulated with Povidone Iodine BP 2% w/v, designed to maintain oral hygiene and prevent infections. Povidone iodine is a broad-spectrum antimicrobial agent, active against bacteria, viruses, and fungi. PROVAMED 2% is widely recommended by dentists and ENT specialists for its ability to control oral microbial growth, relieve minor irritations, and support recovery after dental procedures. It is a trusted solution for both preventive and therapeutic oral care.\n\nUses\n\nPROVAMED 2% mouthwash is suitable for a variety of oral health needs, including:\n\nPrevention of Oral Infections: Reduces bacterial and fungal growth in the mouth.\n\nGingivitis and Periodontitis: Helps manage gum inflammation and microbial load.\n\nPost-Dental Procedures: Recommended after tooth extraction, scaling, or minor oral surgeries.\n\nSore Throat and Pharyngitis: Provides relief from mild throat infections.\n\nMouth Ulcers and Stomatitis: Supports faster healing by controlling microbial activity.\n\nDaily Oral Hygiene: Helps maintain fresh breath and healthy gums.\n\nBenefits\n1. Broad-Spectrum Antimicrobial Action\n\nPROVAMED 2% is effective against bacteria, viruses, and fungi, making it a reliable preventive and therapeutic mouthwash.\n\n2. Promotes Oral Healing\n\nSpeeds up recovery from minor oral injuries, mouth ulcers, and post-procedure inflammation.\n\n3. Reduces Discomfort\n\nHelps relieve soreness, redness, and irritation in gums and oral tissues.\n\n4. Convenient and Easy to Use\n\nThe ready-to-use liquid formulation allows for simple oral rinsing.\n\n5. Safe and Trusted\n\nPovidone iodine is clinically proven, widely used, and recognized for its safety when used as directed.\n\nDosage\n\nAdults and Children above 12 years: Rinse with 10–15 ml of PROVAMED 2% for 30–60 seconds, 2–3 times daily.\n\nChildren under 12 years: Use only under medical supervision with a reduced amount.\n\nPost-Dental Procedures: Follow the dentist’s instructions regarding duration and frequency.\n\nImportant: Spit out the mouthwash after use; do not swallow.\n\nSide Effects\n\nPROVAMED 2% is generally well tolerated. Possible side effects may include:\n\nTemporary staining of teeth or tongue\n\nMild burning sensation in the mouth\n\nAltered taste perception\n\nRare side effects include:\n\nAllergic reactions such as rash, itching, or swelling\n\nIncreased soreness if overused\n\nIn case of severe reactions, discontinue use and consult a healthcare professional.\n\nPrecautions and Warning\n\nDo Not Swallow: Intended for oral rinsing only.\n\nAllergy Alert: Avoid if allergic to iodine or povidone iodine.\n\nPregnancy and Breastfeeding: Use only under medical supervision.\n\nMedical Conditions: Exercise caution in patients with thyroid disorders, kidney disease, or iodine sensitivity.\n\nAvoid Eye Contact: Rinse thoroughly if contact occurs.\n\nStorage: Keep in a cool, dry place away from sunlight and out of children’s reach.\n\nConclusion\n\nPROVAMED 2% (Povidone Iodine Mouthwash BP 2% w/v) is a safe and effective solution for maintaining oral hygiene, preventing infections, and supporting recovery from minor oral ailments or dental procedures. Its broad-spectrum antimicrobial properties, ease of use, and proven safety make it a trusted choice for both preventive care and therapeutic use. By incorporating PROVAMED 2% into daily oral hygiene routines or using it as directed post-dental procedures, patients can maintain healthier gums, reduce microbial growth, and prevent oral infections effectively.", "price": 205.0, "discountamount": 61.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2245, "imageuri": "https://productimages.withfloats.com/actual/693fe996f663c8627e8ac951.png", "tileimageuri": "https://productimages.withfloats.com/tile/693fe996f663c8627e8ac951.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-15T10:57:23.837Z", "updatedon": "2025-12-16T05:55:54.82Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/povidone-iodine-bp-2-w-v/2245", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "PROVAMED 2% MOUTHWASH", "category": "DENTAL", "tags": [ "povidone iodine mouthwash", "povidone iodine mouthwash uses", "povidone iodine mouthwash bp 2 w/v uses", "povidone iodine mouthwash bp 2 w/v", "control oral microbial growth", "Reduces bacterial and fungal growth in the mouth", "Helps manage gum inflammation and microbial load." ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693c0f0df827a9801a26dcd7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Isosorbide mononitrate IP 60mg Tablets", "description": "CARDULES ISMN SR 60 delivers Isosorbide Mononitrate IP 60mg in a sustained-release tablet form, designed for long-term prevention of angina in patients with coronary artery disease. Produced by Steris Healthcare Pvt Ltd, this formulation ensures steady drug release over 12-24 hours, optimizing cardiovascular protection with once-daily dosing convenience. It supports heart health by enhancing blood flow without the peaks and troughs of immediate-release options.​\n\nProduct Overview\nCARDULES ISMN SR 60 contains Isosorbide Mononitrate IP 60mg per sustained-release tablet, a pure nitrate metabolite that bypasses first-pass liver metabolism for consistent bioavailability. The SR technology employs a polymer matrix to gradually liberate the active ingredient, maintaining therapeutic plasma levels throughout the day and minimizing tolerance development associated with frequent dosing. Available in strips of 10 tablets, it features a film-coated exterior for easy swallowing and gastro-resistant properties to protect against stomach acid degradation.​\n\nThis higher 60mg strength suits patients requiring intensified prophylaxis after initial titration from lower doses like 30mg or 40mg. It integrates seamlessly into comprehensive cardiac regimens alongside beta-blockers, statins, or aspirin, under cardiologist supervision. Quality manufacturing adheres to IP standards, ensuring purity above 99% with low impurity profiles for safety in chronic use.​\n\nKey Uses\nCARDULES ISMN SR 60 primarily prevents chronic stable angina pectoris by dilating coronary arteries and reducing myocardial oxygen demand during exertion. Patients experience fewer episodes of chest tightness, pressure, or discomfort triggered by physical activity, stress, or cold exposure.​\n\nIt manages coronary artery disease (CAD) by improving collateral circulation and easing ischemia in narrowed vessels. Often prescribed post-angioplasty or alongside lifestyle modifications, it stabilizes symptoms for enhanced daily functioning.​\n\nAdditionally, it supports adjunctive therapy in congestive heart failure or post-myocardial infarction recovery, where vasodilation unloads the heart. Not for acute attacks—use sublingual nitroglycerin instead—but vital for long-term risk reduction.​\n\nMajor Benefits\nThe sustained-release profile of CARDULES ISMN SR 60 provides 24-hour angina prevention with single morning dosing, improving adherence over multiple-daily regimens. This steady vasodilation lowers preload via venous pooling and afterload via arterial relaxation, cutting oxygen consumption by up to 20-30% during stress.​\n\nPatients report increased exercise tolerance, with treadmill tests showing delayed onset of ST-segment depression. Enhanced myocardial perfusion boosts energy levels, enabling return to work, hobbies, or family activities without fear of sudden symptoms.​\n\nCompared to shorter-acting nitrates, tolerance buildup is slower due to a nitrate-free interval built into once-daily use. Cost-effective at higher strengths, it reduces overall healthcare visits and hospitalization risks from unstable angina.​\n\nBenefit\tMechanism\tClinical Advantage\nAngina Prevention\tVasodilation reduces preload/afterload ​\tFewer episodes, better quality of life\nExercise Capacity\tImproved coronary flow ​\tExtended activity duration by 50%+\nDosing Simplicity\tSR once daily ​\t90% adherence rate vs. multiple doses\nHeart Protection\tLowers ischemia risk. ​\tReduced MI recurrence\nPotential Side Effects\nCommon effects include headache (orthostatic or throbbing), especially in the first week, resolving with hydration and dose acclimation—acetaminophen helps manage it. Dizziness, lightheadedness, or postural hypotension may occur; rise slowly from sitting.​\n\nGastrointestinal upset like nausea or flushing affects 5-10% initially. Avoid alcohol or PDE5 inhibitors (e.g., sildenafil) to prevent severe hypotension.​\n\nRarely, reflex tachycardia, rash, or methemoglobinemia arises; monitor liver enzymes in prolonged use. Contraindicated in severe anemia, glaucoma, or recent PDE5 intake—discontinue if allergic reactions appear.​\n\nDosage Guidelines\nInitiate at 30-40mg daily, titrating to 60mg once in the morning on an empty stomach for optimal absorption. Swallow whole; do not crush. A 10-12 hour nitrate-free window (nighttime) prevents tolerance.​\n\nAdjust for renal/hepatic impairment; max 120mg/day. Store below 25°C. Regular ECG and BP checks ensure efficacy.​\nConclusion\nCARDULES ISMN SR 60 stands as a cornerstone in angina prophylaxis, empowering CAD patients with reliable, sustained vascular relief from Steris Healthcare. Consistent use alongside diet, exercise, and smoking cessation maximizes outcomes, but cardiologist oversight remains essential for safety", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2244, "imageuri": "https://productimages.withfloats.com/actual/693c0f14d878634fd7a965ca.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c0f14d878634fd7a965ca.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:48:13.762Z", "updatedon": "2025-12-16T05:41:10.59Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/isosorbide-mononitrate-ip-60mg-tablets/2244", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CARDULES ISMN SR 60", "category": "cardiology", "tags": [ "Isosorbide mononitrate IP 60mg Tablets", "coronary artery disease", "supports heart health by enhancing blood flow", "gastro-resistant properties to protect against stomach acid", "Contraindicated in severe anemia, glaucoma, or recent PDE5" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }